ArticleCureus2025
Human Papilloma Virus (HPV)-Mediated Oropharyngeal Squamous Cell Carcinoma Incidence Relative to Geographic Rates of HPV Vaccination in the United States.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aims to analyze the trends in the incidence of human papilloma virus (HPV)-mediated oropharyngeal squamous cell carcinoma (OPSCC) in relation to geographic rates of HPV vaccination in the United States. Methods The US Cancer Statistics (USCS) database and the National Cancer Institute's (NCI's) Surveillance, Epidemiology and End Results (SEER) program were used for incidence and population data collection; the Centers for Disease Control and Prevention's (CDC) Teen National Immunization Survey provided vaccination data. Incidence of HPV-mediated OPSCC and the HPV vaccination rate were compared and analyzed using t-tests, ANOVA analyses, and linear regression analyses. Results Statistically significant differences between regions of the United States were observed when incidence and vaccination rates of OPSCC were analyzed. When incidence as a function of vaccination rate was analyzed, no significance was noted. Each region had an increase in the OPSCC incidence in the post-vaccine era compared to the pre-vaccine era. Conclusion We cannot conclude that any variance in OPSCC by region is due to HPV vaccination at this time. Because some regions show increased vaccination rates compared to others, it is likely that they will reach herd immunity first and be the first to see a decline in cases as the population ages. Because of the currently insignificant relationship between the vaccination rate over time and incidence rates, additional longitudinal analyses and cohort follow-up studies are needed to further assess the vaccine's impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.